Ro-3306 是一种有效，选择性的 CDK1 抑制剂，对 CDK1，CDK1/cyclin B1 和 CDK2/cyclin E 的 K 值为分别为 20 nM，35 nM 和 340 nM。

RO-3306是一种ATP竞争性抑制剂，选择性细胞周期蛋白依赖性激酶 (Cdk1) 抑制剂（cdk1/cyclin B1 和 cdk1/cyclin A 的 Ki 值分别为 35 和 110 nM）。 增强下游 p53 信号传导。 诱导 G2/M 期 …

RO-3306是一种ATP竞争性的选择性CDK1抑制剂，Ki为20nM，选择性是其他各种人类激酶的15倍多。 RO-3306抑制CDK1/cyclin B1、CDK1/cyclin A、CDK2/cyclin E和CDK4/cyclin D活 …

RO-3306是一种有效的ATP竞争性周期蛋白依赖性激酶（CDK）1抑制剂，对cdk1/cyclin B1和cdk1/cyclin A的Ki值分别为35和110 nM。 细胞周期进程受多种CDK调控。 Cdk1控制细胞周期 …

Ro-3306 is a potent and selective inhibitor of CDK1, with K s of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

RO-3306是一种ATP竞争性的选择性 CDK1 抑制剂， Ki 为20 nM，选择性是其他各种人类激酶的15倍多。 RO-3306可增强p53介导的 Bax 激活和线粒体的凋亡。

RO-3306是一种具有ATP竞争性的选择性 CDK1 抑制剂（Ki 值为20 nM）。 此外，RO-3306 能够增强 p53 介导的 Bax 激活和线粒体的凋亡过程。

RO-3306 is a selective ATP-competitive inhibitor of CDK1. It inhibites CDK1 cyclin B1 activity with Ki of 35 nM, nearly 10-fold selectivity relative to CDK2/cyclin E and over 50-fold relative to …

Cdk1 Inhibitor IV, RO-3306, RO-3306 is a cell-permeable, potent and ATP-competitive inhibitor of Cdk1 (Ki = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively).

RO-3306是一种选择性ATP竞争性CDK1抑制剂。 它能够抑制CDK1/cyclin B1的活性，Ki值为35 nM，它对CDK1/cyclin B1的选择性是CDK2/cyclin E的近10倍，是CDK4/cyclin D的50倍以上 …

Recently, a selective CDK1 inhibitor, RO-3306, has been identified that reversibly arrests proliferating human cells at the G2/M phase border and provides a novel means for cell cycle …

RO-3306 is an ATP-competitive, potent cyclin-dependent kinase (CDK) 1 inhibitor with Ki values of 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A, respectively. Cell cycle progression is …

A 10 mM (2 mg/569 L) solution of Cdk1 Inhibitor IV, RO-3306 (Cat. No. 217699) in DMSO.

We showed that Ro-3306, a CDK1 inhibitor, exerts anti-influenza activity both in vitro and in vivo. Proof-of-concept studies revealed that knockdown of host CDK1 might affect the splicing of …

2022年5月1日 · We showed that Ro-3306, a CDK1 inhibitor, exerts anti-influenza activity both in vitro and in vivo. Proof-of-concept studies revealed that knockdown of host CDK1 might affect …

2021年4月23日 · We performed immunofluorescence and flow cytometry analysis to investigate DNA damage responses in human tumor cells during low and high dose treatments with RO …

Cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulatory protein that specifically controls the G2/M phase transition of the cell cycle. RO-3306 is a selective, ATP-competitive, …

We investigated the effect of CDK1 inhibition on p53 signaling after simultaneous dual blockade using the CDK1 inhibitor RO-3306 and the MDM2 inhibitor Nutlin-3 in AML. Treatment of …